Stockreport
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm
Check Earnings Report
Eric Bjerkholt - Chief Financial Officer Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relations Presentation Unknown Analyst Next up, we have the team from Mirum Pharmaceuticals. So we have Andrew McKibben from the IR side; and Eric Bjerkholt, who is the CFO, hopefully, I pronounced that correctly. Awesome. All right. So before we dive into it, let me just turn it over to you guys for introduction, overview of the company where things stand today. Eric Bjerkholt Chief Financial Officer Great. Thank you, and thank you to Evercore for inviting us to present here today. And as usual, we will be making forward-looking statements. So please refer to our SEC filings for risk factors. So Mirum is a rare disease company. We have 3 approved medicines for rare cholestatic and other diseases. Our guidance for this year is $500 million to $510 million in revenues, and we are cash flow positive, and we expect continued growth from all 3 medicines into next y
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | MIRM | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
MIRM alerts
MIRM alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRM alerts
High impacting Mirum Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
MIRM
NEWS
NEWS
- Stronger 2025 Outlook And Fragile X Trial Start Might Change The Case For Investing In Mirum (MIRM) [Yahoo! Finance][Yahoo! Finance]
- Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome[Business Wire]
- Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences [Yahoo! Finance][Yahoo! Finance]
- Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences[Business Wire]
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)[Business Wire]
- More
MIRM
SEC Filings
SEC Filings
- 12/5/25 - Form SCHEDULE
- 12/2/25 - Form 4
- 12/1/25 - Form 144
- MIRM's page on the SEC website
- More